{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:30:12Z","timestamp":1793464212533,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00347-026-02535-4","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:26:22Z","timestamp":1791491182000},"page":"865-871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genetische Therapien f\u00fcr Morbus Stargardt","Genetic therapies for Stargardt disease"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4693-2061","authenticated-orcid":false,"given":"Georg","family":"Ansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Janeschitz-Kriegl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"De Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gliem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mantian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Pfau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos","family":"Michalakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Kohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bence","family":"Gy\u00f6rgy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Pfau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2535_CR1","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1073\/pnas.1913179117","volume":"117","author":"M Hanany","year":"2020","unstructured":"Hanany\u00a0M, Rivolta\u00a0C, Sharon\u00a0D (2020) Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases. PNAS Nexus 117:2710\u20132716. https:\/\/doi.org\/10.1073\/pnas.1913179117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2535_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100861","volume":"79","author":"FPM Cremers","year":"2020","unstructured":"Cremers\u00a0FPM, Lee\u00a0W, Collin\u00a0RWJ, Allikmets\u00a0R (2020) Clinical spectrum, genetic complexity and therapeutic approaches for retinal disease caused by ABCA4 mutations. Prog Retin Eye Res 79:100861. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100861","journal-title":"Prog Retin Eye Res"},{"key":"2535_CR3","doi-asserted-by":"publisher","unstructured":"Molday\u00a0RS, Garces\u00a0FA, Scortecci\u00a0JF, Molday\u00a0LL (2021) Structure and function of ABCA4 and its role in the visual cycle and Stargardt macular degeneration. Prog Retin Eye Res101036. https:\/\/doi.org\/10.1016\/j.preteyeres.2021.101036","DOI":"10.1016\/j.preteyeres.2021.101036"},{"key":"2535_CR4","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1172\/JCI34316","volume":"118","author":"M Allocca","year":"2008","unstructured":"Allocca\u00a0M, Doria\u00a0M, Petrillo\u00a0M et\u00a0al (2008) Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J\u00a0Clin Invest 118:1955\u20131964. https:\/\/doi.org\/10.1172\/JCI34316","journal-title":"J Clin Invest"},{"key":"2535_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/mt.2009.256","volume":"18","author":"Y Lai","year":"2010","unstructured":"Lai\u00a0Y, Yue\u00a0Y, Duan\u00a0D (2010) Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome \u3009 or = 8.2\u202fkb. Mol Ther 18:75\u201379. https:\/\/doi.org\/10.1038\/mt.2009.256","journal-title":"Mol Ther"},{"key":"2535_CR6","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/gt.2008.78","volume":"15","author":"J Kong","year":"2008","unstructured":"Kong\u00a0J, Kim\u00a0SR, Binley\u00a0K et\u00a0al (2008) Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther 15:1311\u20131320. https:\/\/doi.org\/10.1038\/gt.2008.78","journal-title":"Gene Ther"},{"key":"2535_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ajo.2022.02.013","volume":"240","author":"MA Parker","year":"2022","unstructured":"Parker\u00a0MA, Erker\u00a0LR, Audo\u00a0I et\u00a0al (2022) Three-Year Safety Results of SAR422459 (EIAV-ABCA4) Gene Therapy in Patients With ABCA4-Associated Stargardt Disease: An Open-Label Dose-Escalation Phase I\/IIa Clinical Trial, Cohorts 1\u20115. AJO Int 240:285\u2013301. https:\/\/doi.org\/10.1016\/j.ajo.2022.02.013","journal-title":"Am J Ophthalmol"},{"key":"2535_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42386-0","volume":"14","author":"LM Riedmayr","year":"2023","unstructured":"Riedmayr\u00a0LM, Hinrichsmeyer\u00a0KS, Thalhammer\u00a0SB et\u00a0al (2023) mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy. Nat Commun 14:6578. https:\/\/doi.org\/10.1038\/s41467-023-42386-0","journal-title":"Nat Commun"},{"issue":"7","key":"2535_CR9","volume":"65","author":"D Favre","year":"2024","unstructured":"Favre\u00a0D, Di Scala\u00a0M, Aisa\u00a0I et\u00a0al (2024) Preclinical safety and efficacy of intein-based dual-AAV gene therapy for Stargardt disease. Invest Ophthalmol Vis Sci 65(7):6089","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2535_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt9354","volume":"11","author":"R Ferla","year":"2025","unstructured":"Ferla\u00a0R, Pugni\u00a0E, Lupo\u00a0M et\u00a0al (2025) Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models. Sci Adv 11:eadt9354. https:\/\/doi.org\/10.1126\/sciadv.adt9354","journal-title":"Sci Adv"},{"key":"2535_CR11","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1089\/hum.2023.017","volume":"34","author":"R Li","year":"2023","unstructured":"Li\u00a0R, Jing\u00a0Q, She\u00a0K et\u00a0al (2023) Split AAV8 Mediated ABCA4 Expression for Gene Therapy of Mouse Stargardt Disease (STGD1). Hum Gene Ther 34:616\u2013628. https:\/\/doi.org\/10.1089\/hum.2023.017","journal-title":"Hum Gene Ther"},{"key":"2535_CR12","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1089\/HUM.2018.156","volume":"30","author":"ME McClements","year":"2019","unstructured":"McClements\u00a0ME, Barnard\u00a0AR, Singh\u00a0MS et\u00a0al (2019) An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4-\/- Mice. Hum Gene Ther 30:590\u2013600. https:\/\/doi.org\/10.1089\/HUM.2018.156","journal-title":"Hum Gene Ther"},{"key":"2535_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102311","volume":"35","author":"A Doi","year":"2024","unstructured":"Doi\u00a0A, Delaney\u00a0C, Tanner\u00a0D et\u00a0al (2024) RNA exon editing: Splicing the way to treat human diseases. Mol Ther Nucleic Acids 35:102311. https:\/\/doi.org\/10.1016\/j.omtn.2024.102311","journal-title":"Mol Ther Nucleic Acids"},{"key":"2535_CR14","volume":"64","author":"S Slomovic","year":"2023","unstructured":"Slomovic\u00a0S, Doi\u00a0A, Gray\u00a0J et\u00a0al (2023) ABCA4 RNA exon editing in vitro and in vivo. Invest Ophthalmol Vis Sci 64:3869","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2535_CR15","unstructured":"FDA approves trial plan and fast tracks Ascidian Therapeutics\u2019 ACDN-01\u00a0in Stargardt Disease | Eye Care Network - Ophthalmology Times. https:\/\/www.ophthalmologytimes.com\/view\/fda-approves-trial-plan-and-fast-tracks-ascidian-therapeutics-acdn-01-in-stargardt-disease. Accessed 12\u00a0Aug 2026"},{"key":"2535_CR16","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41591-024-03422-8","volume":"31","author":"A Muller","year":"2025","unstructured":"Muller\u00a0A, Sullivan\u00a0J, Schwarzer\u00a0W et\u00a0al (2025) High-efficiency base editing in the retina in primates and human tissues. Nat Med 31:490\u2013501. https:\/\/doi.org\/10.1038\/s41591-024-03422-8","journal-title":"Nat Med"},{"key":"2535_CR17","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/s41436-018-0420-y","volume":"21","author":"M Bauwens","year":"2019","unstructured":"Bauwens\u00a0M, Garanto\u00a0A, Sangermano\u00a0R et\u00a0al (2019) ABCA4-associated disease as a model for missing heritability in autosomal recessive disorders: novel noncoding splice, cis-regulatory, structural, and recurrent hypomorphic variants. Genet Med 21:1761\u20131771. https:\/\/doi.org\/10.1038\/s41436-018-0420-y","journal-title":"Genet Med"},{"key":"2535_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.omtn.2020.06.007","volume":"21","author":"M Khan","year":"2020","unstructured":"Khan\u00a0M, Arno\u00a0G, Fakin\u00a0A et\u00a0al (2020) Detailed Phenotyping and Therapeutic Strategies for Intronic ABCA4 Variants in Stargardt Disease. Mol Ther Nucleic Acids 21:412\u2013427. https:\/\/doi.org\/10.1016\/j.omtn.2020.06.007","journal-title":"Mol Ther Nucleic Acids"},{"key":"2535_CR19","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41436-018-0414-9","volume":"21","author":"R Sangermano","year":"2019","unstructured":"Sangermano\u00a0R, Garanto\u00a0A, Khan\u00a0M et\u00a0al (2019) Deep-intronic ABCA4 variants explain missing heritability in Stargardt disease and allow correction of splice defects by antisense oligonucleotides. Genet Med 21:1751\u20131760. https:\/\/doi.org\/10.1038\/s41436-018-0414-9","journal-title":"Genet Med"},{"key":"2535_CR20","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.omtn.2023.02.020","volume":"31","author":"M Kaltak","year":"2023","unstructured":"Kaltak\u00a0M, de Bruijn\u00a0P, Piccolo\u00a0D et\u00a0al (2023) Antisense oligonucleotide therapy corrects splicing in the common Stargardt disease type 1\u2011causing variant ABCA4 c.5461-10T\u3009C. Mol Ther Nucleic Acids 31:674\u2013688. https:\/\/doi.org\/10.1016\/j.omtn.2023.02.020","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"2535_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s43856-024-00712-7","volume":"5","author":"DW Karjosukarso","year":"2025","unstructured":"Karjosukarso\u00a0DW, Bukkems\u00a0F, Duijkers\u00a0L et\u00a0al (2025) Preclinical assessment of splicing modulation therapy for ABCA4 variant c.768G\u3009T in Stargardt disease. Commun Med 5(1):5\u201325. https:\/\/doi.org\/10.1038\/s43856-024-00712-7","journal-title":"Communications Medicine"},{"key":"2535_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ajo.2020.08.042","volume":"222","author":"PL M\u00fcller","year":"2021","unstructured":"M\u00fcller\u00a0PL, Gliem\u00a0M, McGuinnes\u00a0M et\u00a0al (2021) Quantitative Fundus Autofluorescence in ABCA4-Related Retinopathy -Functional Relevance and Genotype-Phenotype Correlation. AJO Int 222:340\u2013350. https:\/\/doi.org\/10.1016\/j.ajo.2020.08.042","journal-title":"Am J Ophthalmol"},{"key":"2535_CR23","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41434-024-00455-z","volume":"31","author":"M Akula","year":"2024","unstructured":"Akula\u00a0M, McNamee\u00a0SM, Love\u00a0Z et\u00a0al (2024) Retinoic acid related orphan receptor \u03b1 is a genetic modifier that rescues retinal degeneration in a mouse model of Stargardt disease and Dry AMD. Gene Ther 31:413\u2013421. https:\/\/doi.org\/10.1038\/s41434-024-00455-z","journal-title":"Gene Ther"},{"key":"2535_CR24","unstructured":"Ocugen Announces Publication of Phase\u00a01 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy | Ocugen, Inc. https:\/\/ir.ocugen.com\/news-releases\/news-release-details\/ocugen-announces-publication-phase-1-gardian1-trial-results\/. Accessed 7\u00a0Apr 2026"},{"key":"2535_CR25","unstructured":"Alnylam Pharmaceuticals Inc (2022) Alnylam Corporate Presentation. https:\/\/investors.alnylam.com\/sites\/default\/files\/pdfs\/ALNY-Corporate-Presentation-Oct.v1.pdf. Zugegriffen: 7. Apr. 2026"},{"key":"2535_CR26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1126\/science.1190897","volume":"329","author":"V Busskamp","year":"2010","unstructured":"Busskamp\u00a0V, Duebel\u00a0J, Balya\u00a0D et\u00a0al (2010) Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science 329:413\u2013417. https:\/\/doi.org\/10.1126\/science.1190897","journal-title":"Science"},{"key":"2535_CR27","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1167\/iovs.13-13768","volume":"55","author":"WC Huang","year":"2014","unstructured":"Huang\u00a0WC, Cideciyan\u00a0AV, Roman\u00a0AJ et\u00a0al (2014) Inner and outer retinal changes in retinal degenerations associated with ABCA4 mutations. Invest Ophthalmol Vis Sci 55:1810\u20131822. https:\/\/doi.org\/10.1167\/iovs.13-13768","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2535_CR28","unstructured":"Nanoscope Therapeutics Announces Publication of STARLIGHT Phase\u00a02\u00a0Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease - Nanoscope Therapeutics. https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/. Accessed 7\u00a0Apr 2026"},{"key":"2535_CR29","unstructured":"GenSight Biologics Announces\u00a01 Year Safety data and Efficacy signals from PIONEER Phase\u00a0I\/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa"},{"key":"2535_CR30","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa2501396","volume":"394","author":"FG Holz","year":"2026","unstructured":"Holz\u00a0FG, Le Mer\u00a0Y, Muqit\u00a0MMK et\u00a0al (2026) Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD. N Engl J Med 394:232\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa2501396","journal-title":"N Engl J Med"},{"key":"2535_CR31","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1056\/NEJMe2514592","volume":"394","author":"J Duncan","year":"2026","unstructured":"Duncan\u00a0J (2026) Restoring Vision for Patients with AMD and Geographic Atrophy. N Engl J Med 394:298\u2013301. https:\/\/doi.org\/10.1056\/NEJMe2514592","journal-title":"N Engl J Med"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02535-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-026-02535-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02535-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:35:51Z","timestamp":1793460951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-026-02535-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2535"],"URL":"https:\/\/doi.org\/10.1007\/s00347-026-02535-4","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.\u00a0Ansari, L.\u00a0Janeschitz-Kriegl, P.\u00a0De Angeli, M.\u00a0Gliem, M.\u00a0Wang, K.\u00a0Pfau, S.\u00a0Michalakis, S.\u00a0Kohl und B.\u00a0Gy\u00f6rgy geben an, dass kein Interessenkonflikt besteht. M. Pfau war Investigator in der Belite Bio DRAGON Studie (NCT05244304).","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}